A Case of Tumor Necrosis Factor-α Inhibitors-induced Pustular Psoriasis

Park, Jae-Jeong; Lee, Seung−Chul

doi:10.5021/ad.2010.22.2.212

Cited by 16 publications

(9 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As far as we know, this is the first report of a serum cytokine analysis in PD-PSV. TNF-α is a prominent cytokine that is associated with most inflammatory skin diseases 4 . The high IL-8 concentrations imply neutrophil chemotaxis, as shown by the histological findings.…”

mentioning

confidence: 99%

Pyodermatitis-Pyostomatitis Vegetans Associated with Crohn's Disease

Kim

2015

Ann Dermatol

View full text Add to dashboard Cite

mentioning

confidence: 99%

Pyodermatitis-Pyostomatitis Vegetans Associated with Crohn's Disease

Kim

2015

Ann Dermatol

View full text Add to dashboard Cite

“…Bu yüzden olgu patoloji ile tekrar değerlendirilerek Andrews püstüler bakteridi olarak kabul edildi, ancak psoriasis ile ayırımı net olmadığı için psoriasiform erüpsiyon olarak değerlendirildi. Anti TNF ajanlarla tedavi alan birçok hastada psoriasiform erüpsiyon ya da psoriasisin farklı klinik formlarının gelişimi gözlenmiştir 1,2,[7][8][9] . Anti TNF-α tedavisiyle gelişen psoriasisin en sık gözlenen formu olgumuzdaki gibi simetrik lokalize palmoplantar püstüler erüpsiyondur.…”

Section: Discussionunclassified

“…Anti TNF ilaçlara bağlı gelişen kutanöz yan etkilerle yaş, cinsiyet ve tedavi süresi arasında net ilişki saptanmamıştır¹. Farklı bir anti TNF ajan tedavisine başlanması ile psoriasis rekürrensi gözlenebilir 9 1,10 . Çoğu hastada psoriasis benzeri yan etkiler topikal steroid tedavisi ile geriler, bazılarında ise fototerapiye gerek duyulur.…”

Section: Discussionunclassified

Pustular bakterid of Andrews during infiliximab therapy for ankylosing spondylitis: A case report

Esener¹,

Mevlitoğlu²

2014

TURKDERM

View full text Add to dashboard Cite

Cutaneous side effects during anti TNF therapies can be classified by their clinical and histopathologic features. Infusion and injection side reactions, vasculitis, psoriasis and psoriasiform eruption, drug-induced lupus, cutaneous infections, eczematous and lichenoid reactions, granulomatous diseases, cutaneous lymphoma, morphea, non-melanoma skin carcinomas, and melanoma are the dermatologic side effects that can be seen during anti TNF therapies. In this case report, we aimed to emphasize the cutaneous side effects during anti TNF agent therapies. Pustular bacterid of Andrews has never been reported as a side effect during anti TNF therapies. In fact, it can be classified as a local form of pustular psoriasis. Here, we report a case of pustular bacterid of Andrews as a psoriasiform side effect seen during infliximab therapy.

show abstract

“…Acitretin can be useful to treat flares of pustular psoriasis, such as may occasionally occur on the distal extremities as a paradoxical reaction to biologic therapy. 34 Characteristic adverse effects include mucocutaneous dryness and other dermatologic abnormalities, as well as triglyceride elevations; laboratory monitoring should comprise liver function tests (LFTs), fasting lipids, complete blood cell count (CBC), and renal function tests. 28 The high teratogenicity of retinoids and associated pregnancy category X rating limit their use in women of childbearing potential, who must be thoroughly counseled on the importance of contraception and the need for routine pregnancy testing.…”

Section: General Guidelines For Dosing and Monitoring Medications In mentioning

confidence: 99%

Managing Patients With Psoriasis in the Busy Clinic

Armstrong

Aldredge

Yamauchi³

2015

J Cutan Med Surg

View full text Add to dashboard Cite

Psoriasis is a common inflammatory disease with significant comorbidities, whose management can be challenging given the variety of treatment options. It is critical for nurse practitioners, physician assistants, general practitioners, and dermatology trainees to have useful information about the treatment and monitoring of patients with psoriasis. Although certain aspects of care apply to all patients, each therapeutic agent has its own nuances in terms of assessments, dosing, and monitoring. The most appropriate treatment is based not only on disease severity but also on comorbid conditions and concomitant medications. These practitioners are vital in facilitating patient care by thorough understanding of systemic agents, selection criteria, dosing, and recommended monitoring. This article provides high-yield practical pearls on managing patients with moderate to severe psoriasis. It includes case-based discussions illustrating considerations for special populations, such as pregnant women, children, and patients with comorbidities (eg, human immunodeficiency virus infection, hepatitis C, hepatitis B, and history of malignancy).

show abstract

A Case of Tumor Necrosis Factor-α Inhibitors-induced Pustular Psoriasis

Cited by 16 publications

References 14 publications

Pyodermatitis-Pyostomatitis Vegetans Associated with Crohn's Disease

Pyodermatitis-Pyostomatitis Vegetans Associated with Crohn's Disease

Pustular bakterid of Andrews during infiliximab therapy for ankylosing spondylitis: A case report

Managing Patients With Psoriasis in the Busy Clinic

Contact Info

Product

Resources

About